Trastuzumab Deruxtecan

Evidence Level: L5

Predicted Indications: 1

Trastuzumab Deruxtecan

Pharmacist Assessment Report

Trastuzumab Deruxtecan: From HER2-Directed Cancer Therapy to Drug-Induced Osteoporosis

One-Sentence Summary

Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate marketed in Canada as ENHERTU. The approved indication text was not available in the data compiled for this report. The TxGNN model (deep learning) predicts it may be effective for drug-induced osteoporosis, but no clinical trials and no publications currently support this prediction. The score comes from the model and may reflect similarities the model learned between related diseases, not biological evidence.

Quick Overview

Item	Content
Original Indication	Not available in the compiled data (the Canadian license record has no indication text)
Predicted New Indication	Drug-induced osteoporosis
TxGNN Prediction Score	0.9931
Evidence Level	L5 (model prediction only)
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on general knowledge, trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor payload to HER2-expressing cells. Its use is in HER2-expressing cancers, notably breast cancer.

The prediction is difficult to justify mechanistically. No plausible link between a HER2-targeted cytotoxic conjugate and bone metabolism or drug-induced bone loss is evident. The high score (rank 11,995 in the model’s ordering) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It should not be read as evidence of benefit.

Clinical Trial Evidence

Currently no related clinical trials registered for drug-induced osteoporosis.

Literature Evidence

Currently no related literature available for drug-induced osteoporosis.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02514400	ENHERTU	Not specified	Not specified

Cytotoxicity

Item	Content
Cytotoxicity Classification	Antibody-drug conjugate with a cytotoxic topoisomerase I inhibitor payload (targeted therapy delivering a cytotoxic agent)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions; haematological parameters and respiratory status are generally relevant
Handling Protection	Follow institutional cytotoxic drug handling regulations

Safety Considerations

Drug Interactions: The interaction query found 42 interacting drugs in total. Examples flagged as Major include deferiprone, samarium (153Sm) lexidronam, adalimumab, baricitinib, certolizumab pegol, cladribine, leflunomide, and natalizumab. Examples flagged as Moderate include palifermin, strontium chloride Sr-89, roflumilast, chloramphenicol, alefacept, alemtuzumab, anakinra, azathioprine, canakinumab, dimethyl fumarate, and niraparib. Many involve immunosuppressive or myelosuppressive agents.
Respiratory risk: The retrieved literature includes case reports of interstitial lung disease and pneumonitis associated with this drug, which is relevant to any airway-related use.
Other reported adverse events: Case reports describe reversible Fanconi syndrome and dermatomyositis with interstitial pneumonia.

Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for drug-induced osteoporosis has no clinical, literature, or mechanistic support (Evidence Level L5). A systemic cytotoxic ADC with known serious toxicities, including lung toxicity, offers an unfavourable risk-benefit profile for a non-oncologic bone condition.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data and the approved indication text for the Canadian license
Preclinical or mechanistic evidence linking the drug to bone metabolism
A risk-benefit assessment justifying systemic cytotoxic exposure in a non-oncology population
Any registered trials or published studies for the predicted indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.